NUMD · XBRL financial data
Nu-Med Plus financial statements, every quarter
The same tables from 13 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal quarters (NUMD's year ends in late December)
| In thousands of dollars | Mar 31, 2022 | Dec 31, 2022 | Mar 31, 2023 | Jun 30, 2023 | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Sep 30, 2024 | Dec 31, 2024 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — | 0 | 0 |
| General and administrative | 3 | 7* | 6 | 7 | 9 | 6* | 6 | 9 | 6* | year only | 5 | 8 |
| Total operating expenses | 60 | 6* | 27 | 23 | 15 | 55* | 21 | 17 | 9* | year only | 13 | 23 |
| Operating income (loss) | (60) | (6)* | (27) | (23) | (15) | (55)* | (21) | (17) | (9)* | year only | (13) | (23) |
| Interest expense | — | year only | 1 | 1 | 1 | 1* | 1 | 1 | 1* | year only | 3 | 3 |
| Income tax expense (benefit) | — | — | — | — | — | — | — | — | — | — | 0 | 0 |
| Net income (loss) | (57) | 43* | (28) | (24) | (16) | (57)* | (22) | (19) | (11)* | year only | (16) | 20 |
| Earnings per share, basic USD per share | 0.00 | 0.00* | 0.00 | 0.00 | 0.00 | 0.00* | 0.00 | 0.00 | — | — | 0.00 | 0.00 |
| Earnings per share, diluted USD per share | 0.00 | 0.00* | 0.00 | 0.00 | 0.00 | 0.00* | 0.00 | 0.00 | — | — | — | 0.00 |
| Weighted average shares, basic thousands of shares | 79,348 | 81,348* | 81,348 | 81,348 | 81,348 | 82,640* | 83,548 | 81,348 | — | — | 83,548 | 83,548 |
| Weighted average shares, diluted thousands of shares | 79,348 | 81,348* | 81,348 | 81,348 | 81,348 | 82,640* | 83,548 | 81,348 | — | — | 83,548 | 83,548 |
Balance sheet
CSVFiscal quarters (NUMD's year ends in late December)
| In thousands of dollars | Mar 31, 2022 | Dec 31, 2022 | Mar 31, 2023 | Jun 30, 2023 | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Sep 30, 2024 | Dec 31, 2024 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | 3 | 73 | 53 | 30 | 11 | 7 | 6 | 4 | 2 | 1 | 4 | 5 |
| Accounts receivable | — | — | 4 | — | — | — | — | — | — | — | — | — |
| Total current assets | 8 | 80 | 59 | 37 | 14 | 13 | 9 | 7 | 9 | 8 | 7 | 13 |
| Property and equipment, net | 0 | — | — | — | — | — | — | — | — | 0 | 0 | 0 |
| Right-of-use asset | 5 | — | — | — | — | — | — | — | — | — | — | — |
| Total assets | 8 | 80 | 59 | 37 | 14 | 13 | 9 | 7 | 9 | 8 | 7 | 13 |
| Accounts payable | 46 | 7 | 14 | 14 | 7 | 8 | 16 | 20 | 43 | 48 | 43 | 34 |
| Accrued liabilities | 114 | 1 | 2 | 3 | 5 | 6 | 15 | 17 | 15 | 18 | 21 | 24 |
| Total current liabilities | 197 | 143 | 150 | 152 | 146 | 160 | 178 | 211 | 224 | 279 | 294 | 280 |
| Long-term debt | — | — | — | — | — | — | — | — | — | 0 | 0 | 0 |
| Total liabilities | 197 | 143 | 150 | 152 | 146 | 160 | 178 | 211 | 224 | 279 | 294 | 280 |
| Accumulated deficit | (9,626) | (9,699) | (9,728) | (9,752) | (9,768) | (9,825) | (9,847) | (9,883) | (9,893) | (9,950) | (9,965) | (9,946) |
| Total stockholders' equity | (189) | (63) | (91) | (116) | (132) | (147) | (169) | (205) | (215) | (271) | (287) | (267) |
| Total liabilities and equity | 8 | 80 | 59 | 37 | 14 | 13 | 9 | 7 | 9 | 8 | 7 | 13 |
| Common shares outstanding (cover page) thousands of shares | 79,348 | 81,348 | 81,348 | 81,348 | 81,348 | 83,548 | 83,548 | 83,548 | 83,548 | 83,548 | 83,548 | 83,548 |
Cash flows
CSVFiscal quarters (NUMD's year ends in late December)
| In thousands of dollars | Mar 31, 2022 | Dec 31, 2022 | Mar 31, 2023 | Jun 30, 2023 | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Sep 30, 2024 | Dec 31, 2024 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (loss) | (57) | 43* | (28) | (24) | (16) | (57)* | (22) | (19) | (11)* | year only | (16) | 20 |
| Stock-based compensation | — | 0* | — | — | — | year only | — | — | — | — | — | — |
| Net cash from operating activities | (12) | (24)* | (20) | (23)* | (19)* | (4)* | (0) | — | (2)* | year only | (6) | 1* |
| Net cash from investing activities | 3 | — | — | — | — | — | — | — | — | — | 0 | 0* |
| Net cash from financing activities | — | year only | — | — | — | — | — | — | — | year only | 10 | 0* |
| Net change in cash | — | — | (20) | — | — | — | (0) | — | — | — | — | — |
Compare with peers
SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Nu-Med Plus | 5.4 | 0 | 1.1* | 83.5M | — | 10-QJun 30, 2026 |
| STRATA Skin Sciences | 7,912 | 9,292* | (239)* | 5.9M | 33.1 quarters | 10-KDec 31, 2025 |
| ENDRA Life Sciences | 1,740 | not reported | (928)* | 1.5M | 1.9 quarters | 10-QJun 30, 2026 |
| Catheter Precision | 643 | 1,019 | (2,861)* | 14.4M | 0.6 quarters | 10-QJun 30, 2026 |
| Global Innovative Platforms | 244 | 51 | (134)* | 49.8M | 1.8 quarters | 10-QJun 30, 2026 |
| Interpace Biosciences | 2,688 | 9,131 | 98* | 27.7M | — | 10-QJun 30, 2026 |
| Bluejay Diagnostics | 9,599 | not reported | (1,499)* | 4.5M | 6.4 quarters | 10-QJun 30, 2026 |
| Stimcell Energetics | 6.9 | not reported | (109) | 21.1M | 0.1 quarters | 10-QAug 31, 2026 |
| LogicMark | 3,496 | 3,349 | 83* | 899,759 | — | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.